Structural basis of respiratory syncytial virus neutralization by motavizumab
- NIH
Motavizumab is {approx}tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1002273
- Journal Information:
- Nat. Struct. Mol. Biol., Vol. 17, Issue (2) ; 02, 2010; ISSN 1545-9993
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
Journal Article
·
Fri Sep 16 00:00:00 EDT 2011
· J. Virol.
·
OSTI ID:1002273
+1 more
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Journal Article
·
Mon Oct 17 00:00:00 EDT 2016
· Proceedings of the National Academy of Sciences of the United States of America
·
OSTI ID:1002273
+15 more
Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus
Journal Article
·
Thu Jun 28 00:00:00 EDT 2012
· J. Mol. Biol.
·
OSTI ID:1002273
+4 more